Clinical Trials Browser

Active not recruiting × INDUSTRY × talquetamab × Clear all

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT03399799 2026-03-12

MonumenTAL-1

Phase 1 Active not recruiting

279 enrolled 1 FDA

Other hematologic neoplasm

Hematologic Neoplasms

NCT04586426 2026-01-16

RedirecTT-1

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence